Background {#Sec1}
==========

Inflammatory bowel disease (IBD) and asthma are both immune-mediated diseases that may be rooted in common pathology, as well as shared genetic and environmental risk factors. Aberrant epithelial barrier function in the lung and gastrointestinal tract, as well as abnormal immune responses to environmental factors and pathogens characterize asthma and IBD^[@CR1]--[@CR7]^. The 'hygiene hypothesis' has been proposed for both IBD and asthma, and postulates that children growing up in relatively sterile environments are more likely to develop chronic immune-mediated diseases later in life. Moreover, disruption of early life intestinal microbiota may exacerbate risk of disease development. For example, asthma and IBD are more common among individuals exposed to antibiotics early in life, while breastfeeding decreases the risk of both diseases^[@CR8]--[@CR10]^. Lack of exposure to enteric pathogens early in life may increase the risk of developing immune-mediated diseases, including both asthma and IBD^[@CR11],[@CR12]^. IBD and asthma also share susceptibility genes, including SMAD3 and IL-23R^[@CR13]--[@CR15]^. Both IBD and asthma have become increasingly common in the Western world during the 20th century and these trends are now being echoed in developing countries^[@CR16]--[@CR20]^.

A previous systematic review and meta-analysis found that individuals with asthma were more likely to have a co-occurring gastrointestinal or urinary condition, but did not specifically evaluate the association between asthma and IBD^[@CR21]^. There is growing epidemiologic evidence that asthma and IBD frequently co-occur^[@CR22]--[@CR29]^ and a family history of one disease may influence the risk of developing the other^[@CR30],[@CR31]^. However, studies evaluating the association between these two diseases have used heterogeneous study designs. Specifically, studies have differed in terms of (1) the relative timing of the two diagnoses and (2) the age of participants included in the study. These two factors have resulted in differing conclusions about the co-occurrence of asthma and IBD.

We conducted a systematic review and meta-analysis to summarize and quantify the association between IBD and asthma, as well as evaluating the impact of study and patient characteristics on the association between these two diseases.

Methods {#Sec2}
=======

This systematic review is based on a previously registered protocol^[@CR32]^ and is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines^[@CR33]^.

Study identification and selection {#Sec3}
----------------------------------

We searched MEDLINE, including articles available as online only ahead of print, (1946--1 April 2017) and EMBASE + EMBASE Classic (1947--1 April 2017) for observational epidemiologic studies evaluating the association between asthma and IBD (Crohn's disease, ulcerative colitis (UC), and IBD-type unclassified (IBD-U)). Search terms for IBD and asthma were grouped using the Boolean operator "AND." The complete search strategy is outlined in Supplementary Table [1](#MOESM1){ref-type="media"}. In addition, we hand-searched: (1) references of included studies and relevant review articles; (2) conference abstracts for major gastroenterology meetings (Digestive Diseases Week, American College of Gastroenterology, and United European Gastroenterology Week) and major thoracic meetings (American Thoracic Society Meeting, European Respiratory Society, and American Academy of Chest Physicians Conference) from 2013 to 2017. The review of abstracts and articles identified for full-text review was conducted via crowd sourcing using CrowdScreen SR^[@CR34]^. Crowdsourcing has previously been shown to increase the efficiency of the systematic review process, while maintaining high accuracy during the review process^[@CR34],[@CR35]^. Prior to screening, each member of the CrowdScreen SR Review team was asked to review a test set of 15 abstracts identified by the principal investigator (MEK). The test set included a mix of abstracts that should be included in full-text review and abstracts that should be excluded from further review. Feedback was provided on the accuracy of their initial reviews to enhance performance. Members of the review team were medical students or undergraduate/graduate students in health sciences and all completed the initial test set with a high degree of accuracy. Each abstract and full-text was reviewed independently by at least two members of the review team. Discrepancies for both the abstract and full-text review stages were resolved by MEK.

Studies eligible for inclusion were observational epidemiologic studies (case-control, cohort, or cross-sectional studies) that either compared the rate of asthma in patients with and without IBD or the rate of IBD in patients with and without asthma. No restrictions were placed on date of publication, language, or region of study. Studies reporting on any subtype of IBD (Crohn's disease, UC, or IBD-U) were included. Case reports and case series were excluded, as were studies reporting on the association between pulmonary function tests or other respiratory illnesses with IBD. If multiple studies reported on the same cohort of patients, the study with the most complete cohort of patients was selected for inclusion in the study.

Data extraction and risk of bias {#Sec4}
--------------------------------

The following information was extracted from included studies independently by two investigators (MEK, KB) using a piloted data extraction form in REDCap electronic data capture tools hosted at the Children's Hospital of Eastern Ontario:^[@CR36]^ study characteristics, including the country and years in which the study was conducted; study design; method of identifying and recruiting individuals to participate in the study; the association between asthma and IBD (crude and adjusted, where possible, and the confounders adjusted for in the model); definitions used to identify and/or confirm cases of asthma and IBD; the age of study participants; the timing of exposure relative to the study outcome; and characteristics of individuals included in each study. Discrepancies were resolved by EIB. The risk of bias in individual studies was determined using the Newcastle-Ottawa Scale^[@CR37]^.

Study design and outcomes {#Sec5}
-------------------------

The primary outcomes of our meta-analysis were the association between asthma and either Crohn's disease, UC, or IBD-U. All analyses were conducted separately for Crohn's disease, UC, and IBD-U. For the primary analysis, no restriction was placed on the timing of one diagnosis relative to the other.

Sensitivity analyses evaluating the temporal associations between asthma and IBD were conducted. Specifically, we conducted two sensitivity analyses in which included studies were limited to (1) those in which the diagnosis of asthma preceded the diagnosis with IBD; and (2) those in which the diagnosis of IBD preceded the diagnosis with asthma. Subgroup analyses were conducted based on the age of diagnosis of IBD, defined according to the Montreal classification (pediatric-onset: ≤16, young adult-onset: 17--40, and older adult-onset: \>40)^[@CR38]^ and/or asthma.

Statistical analysis {#Sec6}
--------------------

Analyses were conducted separately for the association between asthma and (1) Crohn's disease; (2) UC; and (3) IBD-U. Relative risks (RR) and their 95% confidence intervals (CI) were pooled to estimate the association between asthma and IBD. Random effects models were used to account for expected heterogeneity across study designs. The most adjusted estimate was used. Odds ratios were assumed to approximate the RR due to the rare prevalence of IBD and asthma. We performed a sensitivity analysis separating case-control from cohort studies.

Between-study heterogeneity was assessed using the *I*^2^ statistic and the Cochran *Q* statistic with *p* \< 0.1 being considered statistically significant. Meta-regression was conducted to explore sources of study heterogeneity based on the source of patients involved in the study (population-based vs. recruited from tertiary-care center) and the country in which the study was conducted.

All statistical analyses were conducted using the meta and metafor packages in R Software version 3.4.2^[@CR39]--[@CR41]^.

Results {#Sec7}
=======

Description of included studies {#Sec8}
-------------------------------

There were 3975 citations identified from the search of MEDLINE and EMBASE. After removing duplicates, 3022 references remained. Of the 97 studies identified for full-text review, 18 of these were included in the meta-analysis (Fig. [1](#Fig1){ref-type="fig"}). One additional study was identified after reviewing references of included studies. Fifteen studies reported the association between asthma and Crohn's disease^[@CR22]--[@CR24],[@CR26]--[@CR29],[@CR42]--[@CR49]^. Sixteen studies reported the association between asthma and UC^[@CR22]--[@CR24],[@CR26]--[@CR30],[@CR42]--[@CR44],[@CR48]--[@CR52]^. One study reported on the association between asthma and IBD-U^[@CR27]^. Characteristics of included studies are described in Table [1](#Tab1){ref-type="table"}.Fig. 1PRISMA flow diagram.Table 1Characteristics of included studiesStudyCountryStudy designData source (years of study)Definition of IBDDefinition of asthmaRelative timing of diagnosesType of IBDMatched variables and covariatesAge of participantsSample sizeBernstein^[@CR23]^CanadaMatched case-controlProvincial health administrative data (1984--2003)Validated algorithm≥5 health care contacts for asthmaAsthma diagnosed before or after IBDCD, UCMatched on age, sex, and rural/urban residencePediatric and adultIBD: 8072 Controls: 80,489Boneberger^[@CR52]^ChileCase-controlTertiary-care center (2009--2010)Routine clinical practiceNot specifiedNot specifiedUCAdjusted for age and sexRange: 6 to 45 years at study entryIBD: 52 Controls: 174Brassard^[@CR42]^CanadaRetrospective cohortProvincial health administrative data (2001--2006)Externally validated algorithm≥3 prescriptions for respiratory medication within 1 year, on at least two separate occasions; the third prescription must have occurred at ≤40 years of ageAsthma diagnosed before IBDCD, UCIncidence rates were standardized based on age and sex≤40 years at asthma diagnosisAsthma: 136,178^a^D'Arienzo^[@CR50]^ItalyCase-controlTertiary-care center (1998)Standard diagnostic criteriaStandard diagnostic criteriaNot specifiedUCNoneRange: 16 to 69 yearsIBD: 50 Controls: 50D'Arienzo^[@CR51]^ItalyMatched case-controlTertiary-care center (2000)Standard diagnostic criteriaStandard diagnostic criteriaNot specifiedUCMatched controls were partners of casesAdultIBD: 45 Controls: 37Gearry^[@CR24]^New ZealandFrequency matched case-controlCanterbury IBD Study (2003--2005)Standard diagnostic criteriaNot specifiedNot specifiedCD, UCFrequency matched based on age (at recruitment) and sex. Adjusts for family history of IBD, smoking status, age, social class at birth, sex, and ethnicityAdultIBD: 1291 Controls: 600Hammer^[@CR43]^United KingdomMatched case-controlTertiary-care center (1952--1965)Standard diagnostic criteriaQuestionnaire or interviewNot specifiedColonic CD, UCNoneNot specifiedIBD: 243 Controls: 319Hemminki^[@CR28]^SwedenProspective cohortNational health administrative data (1964--2007)Hospitalization with an ICD code for IBDHospitalization with an ICD code for asthmaIBD diagnosed after asthmaCD, UCStandardized incidence rates used expected number of cases based on age, sex, year, region, and socioeconomic statusChildren and adultsAsthma: 148,295^c^Kappelman^[@CR44]^United StatesMatched case-controlPharMetrics Patient-Centric Database (2003--2004)Validated algorithmICD code for asthmaNot specifiedCD, UCMatched on age, sex, health plan type, and geographic regionChildren onlyIBD: 1242 Controls: 3353Kuenzig^[@CR22]^CanadaCase-controlPopulation-based health administrative data (1994--2010)Validated algorithmExternally validated algorithm1. Asthma before IBD\
2. Asthma diagnosed before or after IBDCD, UCAge, sex, rural/urban residence, socioeconomic statusChildren and adultsIBD: 5464 Controls: 402,800Livnat^[@CR45]^IsraelCase-controlTertiary-care center (2008--2009^b^)Standard diagnostic criteriaSelf-reportNot specifiedCDNoneChildren and young adultsIBD: 23 Controls: 24Myrelid^[@CR46]^SwedenMatched case-controlCases: Unclear controls: Southeastern Region Population Registry (2000)Standard diagnostic criteriaSelf-reportNot specifiedCDAge, gender, place of residence, and other atopic manifestations (allergic rhinitis, eczema)Range: 18 to 50 yearsIBD: 275 Controls: 777Nakamura^[@CR30]^JapanMatched case-controlCases: Patients receiving financial aid from the Japanese government for the treatment of UC (1988--1990) Controls: Patients on the roster of a health check-up programDiagnosis of UC by treating physician, and confirmation of diagnosis by independent group for approval of financial aidSelf-report questionnaireAsthma before IBDUCMatched on age and sexChildren and adultsIBD: 384 Controls: 384Neilly^[@CR47]^ScotlandMatched case-controlNot specifiedNot specifiedPrevious physician-diagnosed asthma and/or history of persistent or episodic wheeze with breathlessness, responsive to bronchodilator therapyNot specifiedCDMatched on age, sex, and smoking historyAdultsIBD: 29 Controls: 29Peng^[@CR29]^TaiwanFrequency matched retrospective cohortNational health administrative data (2000--2011)ICD codes for IBDICD code for asthma and treated with inhaled corticosteroids, systemic corticosteroids, or inhaled short-acting ß2 agonistsAsthma diagnosed after IBDCD, UCFrequency matched on age, sex, and index year. Adjusted for age, sex, and other comorbidities (rhinitis, chronic sinusitis, atopic dermatitis, and chronic obstructive pulmonary disease)AdultsIBD: 319 Controls: 807Pugh^[@CR48]^UKMatched case-controlTertiary care center; Ileostomy AssociationStandard diagnostic criteriaSelf-reportNot specifiedCD, UCSome controls were partners of cases. Others were matched to cases based on age and sexNot specifiedIBD: 500 Controls: 500Raj^[@CR49]^UKCohortTertiary-care center (1995--2005)Standard diagnostic criteriaConsistent clinical picture with objective evidence of variable outflow obstruction and/or airway hyper-responsivenessIBD preceded the onset of respiratory disease in all cases but 1CD, UCNoneMean age:\
• UC: 61\
• CD: 60Asthma: 893^a^Virta^[@CR26]^FinlandMatched case-controlNational health administrative data (1994--2010)Received special reimbursement for IBDReceived special reimbursement for asthmaAsthma diagnosed before IBDCD, UCMatched on date of birth, sex, and place of residencePediatricIBD: 595 Controls: 2380Weng^[@CR27]^United StatesMatched case-controlKaiser Permanente Medical Care Program (1996--2005)≥2 inpatient or outpatient ICD codes for IBD≥2 inpatient or outpatient ICD codes for asthmaAsthma could be diagnosed either before or after the diagnosis with IBDCD, UC, IBD-UMatched on age, sex, and length of enrolment in health maintenance organization. Adjusted for smoking.Children and adultsIBD: 12,601 Controls: 50,404*CD* Crohn's disease, *IBD* inflammatory bowel disease, *IBD-U* inflammatory bowel disease type unclassified, *ICD* International Classification of Diseases, *UC* ulcerative colitis^a^The risk of IBD in patients with asthma was compared to the previously reported risk of IBD in the general population^b^Years of study obtained from study protocol on clinicaltrials.gov^c^The risk of IBD in patients with asthma was compared to the number of cases that would be expected if there was no association between asthma and IBD

Risk of bias of included studies {#Sec9}
--------------------------------

The risk of bias among included case-control and cohort studies is summarized in Supplementary Tables [3](#MOESM1){ref-type="media"} and [4](#MOESM1){ref-type="media"}, respectively. The majority of studies were conducted using population-based health administrative data or tertiary-care studies enrolling consecutive patients. Bias may have been introduced to case-control studies based on the controls included in the studies: one study included hospital staff^[@CR50]^, one included partners of cases^[@CR51]^, four included hospitalized patients or patients visiting a clinic for reasons not related to IBD or asthma^[@CR30],[@CR43],[@CR45],[@CR52]^, and one included a mix of partners of cases and non-IBD patients^[@CR48]^. Nine case-control studies did not explicitly report that controls did not have IBD^[@CR24],[@CR30],[@CR43],[@CR45]--[@CR48],[@CR52],[@CR53]^. Two of the four cohort studies included compared the frequency with which asthma and IBD co-occurred to previously published estimates of the rate of either asthma or IBD in the general population^[@CR42],[@CR49]^.

Association between asthma and IBD {#Sec10}
----------------------------------

Asthma and Crohn's disease were associated (pooled RR 1.31, 95% CI 1.16 --1.47, 15 studies, 824,173 participants; heterogeneity: *I*^2^ = 88%, *p* \< 0.0001; Fig. [2](#Fig2){ref-type="fig"}). There was a significant association between UC and asthma (pooled RR 1.30, 95% CI 1.21--1.40, 16 studies, 819,714 participants; heterogeneity: *I*^2^ = 93%, *p* \< 0.0001; Fig. [3](#Fig3){ref-type="fig"}). Asthma and IBD-U were associated in a single study (OR 1.9, 95% CI 1.6--2.4, 51,459 participants)^[@CR27]^.Fig. 2Association between asthma and Crohn's disease.Fig. 3Association between asthma and ulcerative colitis.

Explaining heterogeneity: study design {#Sec11}
--------------------------------------

The association between asthma and IBD was consistently elevated in both case-control and cohort studies (Table [2](#Tab2){ref-type="table"}). Although 22% of heterogeneity was accounted for by study design in studies evaluating the association between asthma and UC, significant heterogeneity persisted (residual heterogeneity: *I*^2^ = 91%, *p* \< 0.0001). Separately analyzing case-control and cohort studies in Crohn's disease did not account for any heterogeneity (residual heterogeneity: *I*^2^ = 88%, *p* \< 0.0001).Table 2Results of subgroup analyses and meta-regression based on study designType of IBDStudy designRR (95% CI)HeterogeneityNumber of studiesNumber of participantsSubgroup differencesResidual heterogeneityCrohn's diseaseCase-control1.25 (1.05--1.50)*I*^2^ = 89%11513,008*p* = 0.24 REF*I*^2^ = 69%\
*R*^2^ = 0%\
*p* \< 0.0001Cohort1.45 (1.23--1.71)*I*^2^ = 82%4311,165*β* 1.6 (95% CI−0.14 to 0.46)Ulcerative colitisCase-control1.33 (1.24--1.42)*I*^2^ = 89%12512,807*p* = 0.78 REF*I*^2^ = 91%\
*R*^2^ = 22%\
*p* \< 0.0001Cohort1.40 (0.99--1.98)*I*^2^ = 94%4306,907*β* −0.046 (95% CI −0.21 to 0.12)

Explaining heterogeneity: data source {#Sec12}
-------------------------------------

Among studies evaluating the association between asthma and Crohn's disease, there was a significantly elevated association in population-based studies (pooled RR 1.43, 95% CI 1.32--1.56, 10 studies, 822,775 participants; heterogeneity: *I*^2^ = 69%) but a protective association in studies recruiting patients from tertiary-care centers (pooled RR 0.89, 95% CI 0.83--0.97, 5 studies, 1398 participants; heterogeneity: *I*^2^ = 0%). Meta-regression based on source of patients (population-based or tertiary-care) accounted for 77% of heterogeneity among studies evaluating the association between asthma and Crohn's disease. However, significant heterogeneity between studies remained (residual heterogeneity: *I*^2^ = 59%, *p* \< 0.0001). No heterogeneity could be accounted for in studies evaluating the association between asthma and ulcerative colitis (residual heterogeneity: *I*^2^ = 94%, *p* \< 0.0001). Results of meta-regression and subgroup analyses based on source of patients are summarized in Table [3](#Tab3){ref-type="table"}.Table 3Results of subgroup analyses and meta-regression based on source of study participantsType of IBDData sourceRR (95% CI)HeterogeneityNumber of studiesNumber of participantsSubgroup differencesResidual heterogeneityCrohn's diseasePopulation-based or health maintenance organization1.43 (1.32--1.56)*I*^2^ = 69%10822,775*p* \< 0.0001 REF*I*^2^ = 59%\
*R*^2^ = 77%\
*p* = 0.0024Tertiary-care center, not stated, or other0.89 (0.83--0.97)*I*^2^ = 0%51398*β* −0.48 (95% CI −0.65 to −0.30)Ulcerative colitisPopulation-based or health maintenance organization1.29 (1.13--1.46)*I*^2^ = 94%9816,528*p* = 0.94 REF*I*^2^ = 94%\
*R*^2^ = 0%\
*p* \< 0.0001Tertiary-care center, not stated, or other1.30 (1.08--1.56)*I*^2^ = 92%73186*β* 0.012 (95% CI −0.20 to 0.22)

Explaining heterogeneity: location of study {#Sec13}
-------------------------------------------

Differences across countries were observed in the association between asthma and Crohn's disease (*p* \< 0.0001). Between country differences accounted for 92% of the heterogeneity across case-control studies (residual heterogeneity: *I*^2^ = 33%, *p* = 0.16) evaluating the association between asthma and Crohn's disease (Table [4](#Tab4){ref-type="table"}).Table 4Results of subgroup analyses and meta-regression based on study locationType of IBDCountryRR (95% CI)HeterogeneityNumber of studiesNumber of participantsSubgroup differencesResidual heterogeneityCrohn's DiseaseCanada1.34 (1.24--1.45)*I*^2^ = 64%3588,067*p* \< 0.0001 REF*I*^2^ = 33%\
*R*^2^ = 92%\
*p* = 0.16Finland2.33 (1.41--3.86)--11165*β* 0.55 (0.036 to 1.07)Israel0.78 (0.55--1.10)--147*β* −0.54 (−0.91 to −0.17)New Zealand1.46 (1.07--1.99)--11238*β* 0.087 (−0.25 to 0.42)Sweden1.61 (1.41--1.83)*I*^2^ = 0%2148,347*β* 0.18 (0.0014 to 0.35)Taiwan1.50 (1.31--1.72)--125,799*β* 0.11 (−0.071 to 0.30)United Kingdom0.90 (0.83--0.97)*I*^2^ = 0%41351*β* −0.39 (−0.54 to −0.25)United States1.39 (1.13--1.71)*I*^2^ = 47%257,159*β* 0.062 (−0.10 to 0.23)Ulcerative colitisCanada1.28 (1.03--1.60)*I*^2^ = 98%3583,902*p* \< 0.0001 REF*I*^2^ = 96%\
*R*^2^ = 0%\
*p* \< 0.0001Chile0.90 (0.77--1.06)--1226*β* −0.35 (−0.80 to 0.099)Finland1.11 (0.68--1.81)--11810*β* −0.14 (−0.79 to 0.50)Italy1.61 (1.25--2.07)*I*^2^ = 84%2182*β* 0.22 (−0.13 to 0.57)Japan0.73 (0.32--1.68)--1768*β* −0.56 (−1.50 to 0.37)New Zealand0.93 (0.67--1.29)--11253*β* −0.32 (−0.85 to 0.21)Sweden1.54 (1.37--1.74)--1148,295*β* 0.18 (−0.26 to 0.62)Taiwan1.46 (1.03--2.07)--121,541*β* 0.13 (−0.42 to 0.68)United Kingdom1.29 (1.09--1.54)*I*^2^ = 66%32010*β* 0.031 (−0.31 to 0.37)United States1.32 (1.07--1.62)*I*^2^ = 41%259,727*β* 0.0018 (−0.37 to 0.37)

Similarly, differences between countries were noted for the association between asthma and UC (*p* \< 0.0001; Table [4](#Tab4){ref-type="table"}). However, no heterogeneity could be accounted for by country (residual heterogeneity: *I*^2^ = 96%; *p* \< 0.0001).

Sensitivity analysis: relative timing of diagnoses {#Sec14}
--------------------------------------------------

When restricting the analysis to studies in which the diagnosis of asthma preceded the diagnosis of Crohn's disease, there was a significant association (pooled RR 1.49, 95% CI 1.27--1.74, 4 studies, 691,525 participants; heterogeneity: *I*^2^ = 86%, *p* \< 0.0001; Supplementary Figure [1](#MOESM1){ref-type="media"}). In studies in which the diagnosis of asthma preceded the diagnosis of UC, the two diseases were not significantly associated (pooled RR 1.21, 95% CI 0.98--1.51, 5 studies, 692,228 participants; *I*^2^ = 97%, *p* \< 0.0001; Supplementary Figure [2](#MOESM1){ref-type="media"}).

Patients previously diagnosed with both Crohn's disease and UC were at an increased risk of new-onset asthma in a single study (Crohn's disease: hazard ratio (HR) 1.50, 95% CI 1.31--1.72; UC: HR 1.46, 95% CI 1.03--2.07)^[@CR29]^.

Subgroup analysis: age at IBD diagnosis {#Sec15}
---------------------------------------

The impact of age at IBD diagnosis on the association between asthma and IBD was evaluated in three studies: one case-control study limited to the association between asthma and UC (408,264 participants)^[@CR22]^, and one cohort study evaluating the association between asthma and both Crohn's disease and UC (136,178 participants)^[@CR42]^, and one cohort study evaluating the association between asthma and IBD (26,300 participants)^[@CR29]^. An additional three studies were limited to pediatric patients and were included in subgroup analyses of pediatric-onset IBD (7554 participants)^[@CR26],[@CR44],[@CR45]^. There was no association between asthma and pediatric-onset Crohn's disease (pooled RR 1.35, 95% CI 0.94--1.93; heterogeneity: *I*^2^ = 92%, Supplementary Figure [3](#MOESM1){ref-type="media"}). Adult-onset Crohn's disease was associated with asthma (20--29 years at diagnosis: incident rate ratio (IRR) 1.18, 95% CI 1.10--1.26; 30--39 years: IRR 1.42, 95% CI 1.32--1.53; 40--49 years: IRR 1.31, 95% CI 1.23--1.41). Pooling across age groups in early adulthood (20--29 and 30--39 years), Crohn's disease and asthma were associated in adults diagnosed in young adulthood (pooled RR 1.29, 95% CI 1.08--1.55; heterogeneity: *I*^2^ = 92%). Meta-regression based on age group did not account for any heterogeneity (residual heterogeneity: *I*^2^ = 92%, *p* \< 0.0001).

Asthma and UC were associated in patients diagnosed with UC as young adults (≤40 years: pooled RR 1.11, 95% CI 1.04--1.19; *I*^2^ = 0%; Supplementary Figure [4](#MOESM1){ref-type="media"}). There was no association between asthma and UC diagnosed during childhood (pooled RR 1.11, 95% CI 0.97--1.28; *I*^2^ = 0%) or after 40 years of age (pooled RR 1.07, 95% CI 0.57--2.00; *I*^2^ = 98%). Among studies analyzing the association between asthma and UC in those diagnosed as older adults, one study suggested there was an increased association while the other identified a protective association. Significant heterogeneity persisted following meta-regression based on age groups (residual heterogeneity: *I*^2^ = 87%, *p* \< 0.0001).

Discussion {#Sec16}
==========

This systematic review and meta-analysis suggests the frequent co-occurrence of asthma with both Crohn's disease and UC. IBD has also been associated with other respiratory disorders (e.g., chronic obstructive pulmonary disease)^[@CR42],[@CR54]^. Further, both asthma and IBD have been associated with other immune-mediated and atopic conditions, including multiple sclerosis, rheumatoid arthritis, diabetes, eczema, and rhinitis^[@CR28],[@CR44],[@CR46],[@CR48],[@CR55]--[@CR59]^. However, there was a high degree of heterogeneity between studies, suggesting that the association between asthma and IBD may vary across populations and be impacted by differences in study methodology.

The association between Crohn's disease and asthma was consistent regardless of the relative timing of the diagnoses of the two diseases (i.e., asthma preceding Crohn's disease or Crohn's disease preceding asthma). However, the risk of asthma was elevated among patients with existing UC but patients with existing asthma did not appear to be at an increased risk of UC. Based on these findings, it is not clear if one disease results in a predisposition to the other or the co-occurrence of these diseases simply occurs due to the commonalities in the physiology of the gut and the lung, as well as shared genetic and environmental risk factors.

Analyses stratified by age at diagnosis of IBD were inconsistent, with some studies suggesting a consistently elevated association between the two diseases across all ages, while others found contradictory age-specific associations. For example, one study found that the association between asthma and UC was decreased among people who were diagnosed with UC between 40 and 49 years of age^[@CR42]^, while another study found an increased risk among patients diagnosed with UC \> 40 years of age^[@CR22]^. As both studies used health administrative data, and neither used an internally validated algorithm to identify cases of asthma, misclassification of asthma may have resulted in bias.

Additionally, failure to account for smoking status may have influenced the findings of these studies. Smoking is associated with an increased risk of Crohn's disease but a decreased risk of UC^[@CR60]^. Of the three included studies that adjusted for smoking status, two reported elevated associations between asthma and Crohn's disease while one suggested that there may be a protective effect of the two diseases but was underpowered to detect a difference^[@CR24],[@CR27],[@CR47]^. Asthma and UC were associated in one study that adjusted for smoking but not the other^[@CR24],[@CR27]^. Differential rates of smoking across ages at IBD diagnosis may also contribute to differences observed in the association between asthma and IBD. For example, smoking is significantly more common among patients who are older at the time of Crohn's disease diagnosis^[@CR61]^. As a result, smokers with Crohn's disease may be at an elevated risk of respiratory disease due to smoking but not their IBD. The decreased rate of smoking among patients with UC may explain the protective association seen in one study^[@CR42]^. Similarly, other environmental risk factors (e.g., air pollution) demonstrate age-specific associations with both asthma and IBD and may contribute to the differences in the age-specific associations between asthma and IBD^[@CR62],[@CR63]^.

A limitation of studies evaluating the associations between two conditions is that patients diagnosed with one condition have higher health services utilization than healthy individuals and may subsequently be more likely to be diagnosed with another condition^[@CR64]^. No study included in our systematic review accounted for increased health care use. As a result, our findings of an increased association between asthma and IBD may have resulted from detection bias.

The association between asthma and Crohn's disease varied across geographic regions. In Canada, New Zealand, Finland, Sweden, Taiwan, and the United States, the association between asthma and Crohn's disease was elevated. However, there was a negative association in the United Kingdom and Israel. Regional differences in the association between asthma and UC were less pronounced. Although the reasons for these regional differences are not known, it is possible that differing penetrance of genetic or environmental risk factors may contribute. For example, the high prevalence of early-life exposure to peanuts has been associated with a decreased risk of peanut allergy in Israel^[@CR65]^. This decreased risk of atopy may also result in a decreased risk of asthma among these children but not impact their elevated risk of developing IBD, due to genetic predisposition of IBD amongst Ashkenazi Jews.

As this is a systematic review, our ability to make conclusions about the co-occurrence of asthma and IBD is limited by the availability and quality of previous studies evaluating the association between these two diseases. Although we included 19 studies in our review, there was high degree of heterogeneity across studies. Heterogeneity was reduced when accounting for study methodology (i.e., study design and source of study participants) in studies analyzing the association between asthma and Crohn's disease but not in the association between asthma and UC. In fact, there was an elevated association between asthma and Crohn's disease in population-based studies, but a protective association between the two diseases in studies conducted using patients recruited from tertiary-care centers. All samples recruiting patients from tertiary-care centers were conducted either in Israel or the United Kingdom. This suggests that there are other underlying differences between studies and populations when it comes to understanding the association between asthma and IBD and we are unable to ascertain if the differences we observed result from differing study design or differences across populations. Specifically, the majority of studies recruiting patients from tertiary-care centers may have introduced selection bias by their choice of controls (e.g., partners of cases). However, similar control groups were selected in studies evaluating the association between UC and asthma included control groups that could similarly have introduced selection bias, yet the association remained similar regardless of the source of patients. In addition, there may be other differences in study design that were not accounted for (e.g., differences in the case definitions for IBD and asthma and variables adjusted for), underlying differences in the study population, or the phenotypes of asthma and IBD identified in the study (i.e., disease severity, behavior, management approach).

Conclusions {#Sec17}
===========

Asthma is associated with both Crohn's disease and ulcerative colitis. Geographic differences, as well as differences in study design, contribute to this heterogeneity. We were unable to determine whether one disease increases the risk of the other or if both arise due to commonalities in pathology and shared risk factors. Future well-designed observational research should attempt to address these issues in their study design.

Study Highlights {#Sec019}
================

What is current knowledge {#Sec20}
-------------------------

Asthma and the inflammatory bowel diseases share environmental, genetic, and microbial risk factors

What is new here {#Sec021}
----------------

Asthma is associated with both Crohn's disease and ulcerative colitisThe relationship between these two diseases appears to vary by region
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